Revolutionizing Lentiviral Vector Production
Leveraging three decades as viral vector CDMO, MillIporeSigma delivers the ultimate solution for high-quality, high-titer lentivirus production to better support cell and gene therapies.
From preclinical development through manufacturing, MilliporeSigma is a trusted and experienced CDMO partner for lentiviral vectors. Their high titer, high-quality, end-to-end lentivirus platform streamlines cell or gene therapies to GMP in less than 12 months.
Addressing the needs of cell and gene therapy innovators, the lentivirus platform is intentionally designed to ensure optimized and de-risked lentivirus production.
- Industry-leading titer: 4 x 108 TU/mL
- Maximized batch yields: 20% recovery
- Exclusive, off-the-shelf packaging plasmids
- GOI plasmid production support
- GMP-banked HEK293T cell line and media
- Clinical and commercial GMP production
- Fill/finish services
- Comprehensive analytical toolbox
In this series, discover how MilliporeSigma can support your cell or gene therapy with their lentiviral vector CDMO solutions.
High titer, high yield, high-quality, and de-risked lentivirus manufacturing. The ultimate solution to bring your lentivirus-based cell or gene therapy to GMP in <12 months.
Using DoE and supplementary studies, the upstream and downstream workflows were optimized for scalability, quality, and high performance to de-risk lentiviral vector production.
Click here to read the whitepaper
